VetMedOtitis externa in dogs: first-line topical combination products — what the trials actually compare — POSSIBLE
In dogs with uncomplicated bacterial/yeast otitis externa, do antimicrobial + glucocorticoid combination products outperform antimicrobial-only products for clinical and cytological cure?
Shelf #142 · gate-verified and approved by the developer
POSSIBLE: Combination antimicrobial-plus-glucocorticoid ear products are effective first-line treatment — in a randomised vehicle-controlled field trial the combination gel's treatment success rate was 64.78% vs 43.42% for its vehicle (Forster 2018) — but no carded trial has ever compared a combination product against an antimicrobial-only product, which is the comparison this shelf's question asks about. The one trial that isolates the antimicrobial contribution found no added value in allergic erythemato-ceruminous otitis: hydrocortisone aceponate alone matched a prednisolone–miconazole–polymyxin combination on every clinical and cytological measure, with good-to-excellent responses in over 90% of dogs in both groups (Rigaut 2024). Between two combination products, a twice-applied gel and a daily suspension performed identically on clinical success, cytology and culture (King 2018). All three carded trials were conducted and authored by the products' manufacturers (Virbac; Elanco), so this evidence base is graded as an industry licensure base, not independent evidence. The honest bottom line: combinations work; whether their antimicrobial components add anything over glucocorticoid alone in uncomplicated allergic otitis is unproven and, on the only direct test, doubtful; in frankly infected ears the antimicrobial question has never been put to an antimicrobial-only arm. Drafted Nov 10, 2026 (VetMed build, topic #142); all figures from abstracts fetched and verified at drafting.
Rigaut 2024: hydrocortisone aceponate alone matched a prednisolone–miconazole–polymyxin combination on every outcome in allergic erythemato-ceruminous otitis externa
Randomised, multicentric, single-blinded, controlled trial (title's own wording; publication types: Multicenter Study, Randomized Controlled Trial, Veterinary)
Who: Dogs: 201 dogs with erythemato-ceruminous otitis externa (ECOE — allergic otitis with recurrent secondary bacterial and yeast overgrowth detected on cytology) in a multicentre field trial, randomly assigned to a hydrocortisone aceponate (HCA)-only ear spray (n = 97) or an approved combination control product containing prednisolone, miconazole and polymyxin (n = 104), treated for 7–14 days as needed. All four authors are affiliated with Virbac SA, the HCA product's manufacturer.
Result: All clinical parameters (Otitis Index Score-3, hearing test, pruritus and pain visual analogue scales, and cytological scores at days 0, 7, 14, 28 and 42) decreased rapidly and in a similar way, with no significant difference between treatment groups at any time. A good-to-excellent response to treatment was seen in >90% of dogs in both groups as early as day 14, and the treatment was considered safe in all dogs. The authors concluded that, based on these results, it may be necessary to reconsider the routine use of antimicrobial drugs as first-line treatment for ECOE likely caused by an allergic reaction.
Watch out: Industry-conducted licensure-style trial (all authors Virbac SA) built around the sponsor's steroid-only product; 'no significant difference' is not, on the record as fetched, a pre-specified non-inferiority demonstration. The population is allergic ECOE with overgrowth on cytology — not purulent, rod or Pseudomonas otitis — so this null does not licence withholding antimicrobials from frankly infected ears.
Rigaut D, Briantais P, Jasmin P, Bidaud A. Efficacy and safety of a hydrocortisone aceponate-containing ear spray solution in dogs with erythemato-ceruminous otitis externa: A randomised, multicentric, single-blinded, controlled trial. Veterinary Dermatology. 2024;35(2):197-206. PMID: 38093088. Registry ID: none in the record. MeSH: Animals · Dog Diseases/drug therapy · Dogs · Hydrocortisone/adverse effects · Hydrocortisone/analogs & derivatives · Otitis Externa/drug therapy · Otitis Externa/veterinary · Saccharomyces cerevisiae
King 2018: a twice-applied florfenicol–terbinafine–betamethasone gel and a daily hydrocortisone aceponate–miconazole–gentamicin suspension were indistinguishable in 286 dogs with otitis externa
Randomized, controlled, single-blinded, multicenter evaluation (title's own wording; publication type: Randomized Controlled Trial)
Who: Dogs: 286 privately owned dogs with otitis externa in a multicentre field study, randomised to an otic gel containing 1% florfenicol, 1% terbinafine and 0.1% betamethasone acetate applied twice with a one-week interval, or a suspension containing hydrocortisone aceponate, miconazole and gentamicin applied daily for 5 days, after ear cleaning with saline. All authors are employees of Elanco Animal Health, the gel manufacturer's company.
Result: OTIS-3 (otitis index score) decreased significantly (p < 0.0001) by 63% and 64% for the otic gel and by 63% and 61% for the suspension on days 28 and 56 respectively. There was no significant difference between groups at any time point with regard to clinical success, pain, pruritus, overall assessments or otic cytology and culture. The treatment response was considered excellent or good by approximately three quarters of both the clinicians and the owners in both groups. Otitis recurrence at day 56 was seen in 11% of both groups, and no adverse events were attributable to the ear medications.
Watch out: Both arms are antimicrobial-plus-glucocorticoid combinations, so this trial compares products and dosing convenience, not whether a combination beats either component alone. Industry-conducted (all authors Elanco Animal Health employees); the record states the study followed Good Clinical Practice guidelines (VICH GL9).
King SB, Doucette KP, Seewald W, Forster SL. A randomized, controlled, single-blinded, multicenter evaluation of the efficacy and safety of a once weekly two dose otic gel containing florfenicol, terbinafine and betamethasone administered for the treatment of canine otitis externa. BMC Veterinary Research. 2018;14(1):307. PMID: 30305092. Registry ID: none in the record. MeSH: Animals · Anti-Bacterial Agents/administration & dosage · Anti-Bacterial Agents/therapeutic use · Anti-Inflammatory Agents/administration & dosage · Anti-Inflammatory Agents/therapeutic use · Betamethasone/administration & dosage · Betamethasone/therapeutic use · Dog Diseases/drug therapy · Dogs · Drug Combinations · Gels/administration & dosage · Gels/therapeutic use · Naphthalenes/administration & dosage · Naphthalenes/therapeutic use · Otitis Externa/drug therapy · Otitis Externa/veterinary · Terbinafine · Thiamphenicol/administration & dosage · Thiamphenicol/analogs & derivatives · Thiamphenicol/therapeutic use · Treatment Outcome
Forster 2018: two doses of a florfenicol–terbinafine–betamethasone gel beat its vehicle — treatment success 64.78% vs 43.42% at day 45 — in 284 dogs with otitis externa
Randomized, placebo-controlled field trial (record's own wording; publication type: Randomized Controlled Trial; blinding not stated in the record's abstract)
Who: Dogs: 284 dogs with bacterial and/or fungal otitis externa in a multicentre field trial, randomly assigned to receive two doses of the combination gel (florfenicol, terbinafine and betamethasone acetate; Osurnia) or its vehicle (placebo), one week apart, and evaluated through day 45. The primary outcome was the rate of treatment success, defined as a total clinical score of 0, 1 or 2 on day 45. All authors are employees of Elanco Animal Health, the product's manufacturer.
Result: The rate of treatment success was significantly higher in ears treated with the combination gel (64.78%) than with placebo (43.42%) — an absolute difference of about 21 percentage points. There was no significant interaction between efficacy and duration of history, recurrence of otitis or body weight. Adverse events were similar between groups; all dogs treated with the gel maintained their hearing on the 'clap test', and there were no relevant clinical pathology changes.
Watch out: The comparator is the product's own vehicle, so this trial proves the combination beats no active treatment — not that it beats an antimicrobial-only or a glucocorticoid-only product. The record's abstract does not state blinding and none is claimed here. Industry-conducted licensure trial (all authors Elanco employees); the vehicle group's 43.42% success rate also shows how much uncomplicated otitis improves with time, cleaning and an inert gel alone.
Forster SL, Real T, Doucette KP, King SB. A randomized placebo-controlled trial of the efficacy and safety of a terbinafine, florfenicol and betamethasone topical ear formulation in dogs for the treatment of bacterial and/or fungal otitis externa. BMC Veterinary Research. 2018;14(1):262. PMID: 30170597. Registry ID: none in the record. MeSH: Administration, Topical · Animals · Anti-Infective Agents, Local/administration & dosage · Anti-Infective Agents, Local/therapeutic use · Betamethasone/administration & dosage · Betamethasone/therapeutic use · Dog Diseases/drug therapy · Dogs · Drug Combinations · Female · Hearing · Male · Naphthalenes/administration & dosage · Naphthalenes/therapeutic use · Otitis Externa/drug therapy · Otitis Externa/veterinary · Terbinafine · Thiamphenicol/administration & dosage · Thiamphenicol/analogs & derivatives · Thiamphenicol/therapeutic use · Treatment Outcome
Synthesis: combination products beat their vehicle, match each other, and did not beat glucocorticoid alone in allergic otitis — the antimicrobial-only comparison has never been run
Synthesis
Who: Synthesis of the cards above: Rigaut 2024 (201 dogs with allergic erythemato-ceruminous otitis externa, randomised single-blinded, combination vs glucocorticoid-only), King 2018 (286 dogs with otitis externa, randomised single-blinded, combination gel vs combination suspension) and Forster 2018 (284 dogs with bacterial and/or fungal otitis externa, randomised, combination gel vs vehicle). All three trials were conducted by the products' manufacturers.
Result: (1) A combination product is better than its inactive vehicle: treatment success 64.78% vs 43.42% at day 45 (Forster). (2) Two marketed combinations do not differ from each other on clinical success, cytology, culture or recurrence (King). (3) In allergic erythemato-ceruminous otitis, adding antimicrobials to a glucocorticoid showed no measurable advantage over the glucocorticoid alone, with >90% good-to-excellent responses in both arms (Rigaut). The evidence therefore supports combination products as effective first-line treatment, but it does not show that the antimicrobial components are what makes them work in uncomplicated allergic cases.
Watch out: The entire carded base is industry-conducted licensure research: sponsors chose the comparators (vehicle, own or rival combinations, and in Rigaut's case the sponsor's steroid-only spray against a rival combination), and no independent or antimicrobial-only-arm trial was found. Results in erythemato-ceruminous allergic otitis should not be transported to purulent, ulcerative or Pseudomonas otitis, where the antimicrobial question is different and untested here.
Synthesis of Rigaut D et al. PMID: 38093088; King SB et al. PMID: 30305092; Forster SL et al. PMID: 30170597. Registry IDs as on the individual cards.
Back to the library index · VetMed home
VetMed is an educational resource, not veterinary advice.